Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 19/20 | 0.51 |
| ▸ | JAK1 | P23458 | 19/20 | 0.51 |
| ▸ | TYK2 | P29597 | 9/20 | 0.51 |
| ▸ | JAK3 | P52333 | 9/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18893906 | 0.95 | IRAK4 (0.51) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL18894024 | 0.94 | IRAK4 (0.52) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL31039847 | 0.94 | IRAK4 (0.52) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL18893912 | 0.93 | IRAK4 (0.54) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL20560477 | 0.92 | IRAK4 (0.51) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL20560453 | 0.92 | JAK2 (0.51) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL29489741 | 0.92 | JAK2 (0.51) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL18893939 | 0.92 | IRAK4 (0.50) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL20560479 | 0.91 | JAK2 (0.58) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL30273461 | 0.91 | JAK2 (0.58) | IRAK4JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230206644-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20220024945-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220024945-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3740488-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2020-11-25 | — | — | EP | disclosed |
| US-20200339604-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS | GENENTECH, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| EP-3630767-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2020-04-08 | — | — | EP | disclosed |
| US-20200062779-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-02-27 | — | — | US | disclosed |
| WO-2018215390-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-11-29 | — | — | WO | disclosed |
| US-20180334465-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024945-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | IRAK4 27/4885JAK2 1/4885JAK1 2/4885 |
| US-20200062779-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | IRAK4 27/4885JAK2 1/4885JAK1 2/4885 |
| US-20180334465-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | IRAK4 27/4885JAK2 1/4885JAK1 2/4885 |
| US-20200339604-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS | JAK2, JAK1, JAK3 | IRAK4 13/4885JAK2 1/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.